

# UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

#### OMB APPROVAL 3235-OMB Number: 0104 Estimated average burden hours per 0.5 response...

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting		Statement		3. Issuer Name and Ticker or Trading Symbol						
Person *				BioSig Technologies, Inc. [BSGM]						
Holzer Asher		nth/Day/Year)								
(Last) (First) (Middle) C/O BIOSIG TECHNOLOGIES, INC., 8441 WAYZATA BLVD., SUITE 240		07/20/2015		4. Relationship of Rep Person(s) to Issuer (Check all applied X_Director X_Officer (give				5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street)				e below)	below)		6. Individu	ual or Joint/Group		
MINNEAPOLIS, MN 55426				Chief Scientific Advi		or	Filing(Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Tab	le I - Non-	-Derivati	ve Securitio	curities Beneficially Owned				
1. Title of Security (Instr. 4)			Amount of Securities eneficially Owned nstr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Owne	Nature of Indirect Beneficial Ownership Instr. 5)			
Common Stock, \$0.001 par value per share			000		D					
	vho respond ed to respor	to the collect ad unless the	ction of in e form dis	formation plays a c	n contained urrently vali	in this	3 control	SEC 1473 (7-02)		
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration Da (Month/Day/Year	eisable and ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		of 4. Convers or Exerc	sion Coise H	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount of Number of Shares		, I	Security: Direct (D) or Indirect (I) (Instr. 5)			
Options to Purchase Common Stock	(1)	09/21/2019	Common Stock	243,000	\$ 2		D			
Options to Purchase Common Stock	09/01/2014	09/01/2021	Common Stock	75,000	\$ 2.5		D			
Options to Purchase Common Stock	(2)	06/22/2025	Common Stock	25,000	\$ 2.53		D			
Reporting Owner	rs									

	Reporting Owner Name / Address	Relationships					
	Reporting Owner Name / Address		10% Owner	Officer	Other		
3	Holzer Asher C/O BIOSIG TECHNOLOGIES, INC. 8441 WAYZATA BLVD., SUITE 240 MINNEAPOLIS, MN 55426	X		Chief Scientific Advisor			

# **Signatures**

/s/ Kenneth L. Londoner, attorney-in-fact	07/20/2015
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). The options vested 81,000 on September 21, 2013, the first anniversary of the grant, and 81,000 on September 21, 2014, the second
- (1) anniversary of the grant. The remaining 81,000 will vest on September 21, 2015, the third anniversary of the grant. As of the date of this report, the options are vested and exercisable as to 162,000 underlying shares.
- (2) The options vest in 12 consecutive monthly installments beginning one month from June 22, 2015, the date of the grant. As of the date of this report, the options are vested and exercisable as to zero underlying shares.

### Remarks:

Exhibit 24.1 Power of Attorney (furnished herewith)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

### POWER OF ATTORNEY

July 20, 2015

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kenneth L. Londoner as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for, in the name of, and on behalf of the undersigned, place and stead, in any and all capacities, (i) to execute any and all filings required to be made by the undersigned in the undersigned's capacity as an officer or director or both of BioSig Technologies, Inc. pursuant to Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), for, in the name of, and on behalf of the undersigned, (ii) to do and perform any and all acts for, in the name of, and on behalf of the undersigned which said attorney-in-fact determines may be necessary or appropriate to complete and execute any and all such filings, amendments, supplements, and/or exhibits, and any and all other document(s) in connection therewith, (iii) to file such filings, amendments, supplements, exhibits, and/or documents with any governmental office or agency, whether U.S., foreign, state or local government (including, without limitation, the U.S. Securities and Exchange Commission and state securities administrators or commissions), or any stock exchange or stock quotation system (including, without limitation, The NASDAQ Capital Market), as may be required under applicable laws or rules and regulations of any stock exchange or stock quotation system, and (iv) to perform any and all other acts that, in the opinion of said attorney-in-fact and agent, may be of benefit to, in the best interest of, or legally required by or for the undersigned, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent shall do or cause to be done by virtue hereof. The undersigned hereby acknowledges that the foregoing attorney-in-fact and agent, in serving in such capacity at the request of the undersigned, is not assuming any of the responsibilities of the undersigned to comply with Section 16 or Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports under Section 13 or Section 16 of the Exchange Act (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including any amendment, supplement, and/or exhibit thereto), unless earlier revoked by the undersigned in a signed writing delivered to Kenneth L. Londoner.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed and effective as of the date first written above.

/s/ Asher Holzer Asher Holzer